Roche appoints new research and early development head
pharmafile | March 15, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Roche, appointment
Dr John C Reed, Roche’s Head of Pharma Research and Early Development (pRED), is set to leave the company due to personal reasons, it has emerged. Furthermore, it has been announced that current Global Head of the Oncology Discovery and Translational Area for pRED, Dr William Pao, will succeed him in the role, effective 2 April.
A Yale and Harvard graduate and faculty member of the Memorial Sloan-Kettering Cancer Center, Dr Pao has served at Roche since 2014, arriving one year after Dr Reed. Prior to making the move to his current company, he held the dual roles of Professor of Medicine and Director of the Division of Hematology/Oncology at Vanderbilt University, and Director of Personalized Cancer Medicine at Vanderbilt-Ingram Cancer Center.
Roche praised Dr Pao in the announcement of his promotion, noting that he is recognised “for his groundbreaking work in translational medicine, mechanistic and clinical studies of targeted cancer therapeutics, and for his leadership in cancer genomics and personalised medicine”. He is the author of a number of scientific and medical publications, and has served as an advisor to associations including the National Cancer Institute, the American Association for Cancer Research and the American Society of Clinical Oncology. He is also the co-founder of MyCancerGenome, a unified genomics and clinical trial online portal.
“I am delighted with the appointment of one of our most distinguished scientific leaders, William Pao, currently Global Head of the Oncology Discovery and Translational Area for pRED,” commented Roche CEO Severin Schwan. “Since joining Roche in 2014, William has been instrumental in the build-up of cancer immunotherapy and molecular targeted therapies.”
Schwan added: “I am thankful to have had John Reed with Roche over the past five years, and for all his many valuable contributions. I wish John all the best for his future.”
Related Content
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …
Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …
